Pharmacology and pharmacokinetics of fosphenytoin

Neurology

Volumn 46, Issue 6 SUPPL., 1996, Pages

  Browne, Thomas R ^a,c   Kugler, Alan R ^b   Eldon, Michael A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; EPILEPSY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029946975     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.46.6_suppl_1.3s     Document Type: Conference Paper

References (48)

1. Stella V, Higuchi T. Esters of hydantoic acid as prodrugs of hydantoins. J Pharm Sci 1973;62:962.
2. Browne TR, Szabo GK, McEntagert C, et al. Bioavailability studies of drugs with nonlinear pharmacokinetics. II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentration determined by double stable isotope technique. J Clin Pharmacol 1993;33:89-94.
3. Gerber N, Mays DC, Donn KH, et al. Safety, tolerance, and pharmacokinetics of intravenous doses of phosphate ester of 3-hydroxymethyl-5-diphenyl hydantoin: a new prodrug of phenytoin. J Clin Pharmacol 1988;28:1023-1032.
4. Herbranson DE, Kriss-Danziger P. Development and validation of a high performance liquid chromatographic method for the determination of phenytoin prodrug (fosphenytoin) in solutions, parenteral formulations, and active drug substance. J Liquid Chromatogr 1993;16:1143-1161.
5. Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of phenytoin prodrug given IV in patients. Neurology 1990;40:456-460.
6. Cerebyx (fosphenytoin sodium injection) package insert. Morris Plains, NJ: Parke-Davis, 1996.
7. Lai C, Moore P, Matier WL, Quon CY. Bioequivalence of ACC-9653, a phosphate ester prodrug of phenytoin, to phenytoin sodium after IV administration in dogs. Pharmacologist 1987; 29:143.
8. Varia SA, Stella VJ. Phenytoin prodrugs. IV. In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J Pharm Sci 1984;73:1087-1090.
9. Chan YC, Bavda LT, Bobadilla LC, Quon CY. Metabolism and disposition of 14-C-ACC-9653, 3-phosphoromethyl-(4-14-C)-5,5-diphenylhydantoin, in rats. FASEB J 1988;2:A1063.
10. Lai C, Moore P, Matier WL, Quon CY. Comparative pharmacokinetics and bioavailability of phenytoin sodium capsule and IM administration of ACC-9653, a prodrug of phenytoin, in dogs. Fed Proc 1987;46:867.
11. Lai CM, Moore P, Matier WL. Pharmacokinetics and absolute bioavailability of prodrug of phenytoin, ACC-9653, after IM administration in dogs. Acta Pharmacol Toxicol 1988;59(suppl 5):213.
12. Porter RJ, Cereghino JJ, Gladding GD, et al. Antiepileptic drug development program. Cleve Clin Q 1984;51:293-305.
13. Walton NY, Treiman DM. Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. Epilepsy Res 1990;5:165-168.
14. Hartman D, Hartman J, Stampfli H, Quon C, Maher R, Krasula R. Cardiovascular effects of ACC-9653, a prodrug of phenytoin, administered by intravenous injection in anesthetized dogs. Fed Proc 1987;46:708.
15. Smith RD, Brown BS, Maher RW, Matier WL. Pharmacology of ACC-9653 (phenytoin prodrug). Epilepsia 1989;30(suppl 12):515-521.
16. Varia SA, Stella VJ. Phenytoin prodrugs. V. Evaluation of some water-soluble phenytoin prodrug in dogs. J Pharm Sci 1984;73:1080-1087.
17. Browne TR, Davoudi H, Donn KH, et al. Bioavailability of ACC-9653 (phenytoin prodrug). Epilepsia 1989;30(suppl 2): 527-532.
18. Jamerson BD, Donn KH, Dukes GE, et al. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. Epilepsia 1990;31:592-597.
19. Browne TR, LeDuc B. Phenytoin and fosphenytoin: biotransformation. In: Levy RY, Mattson RH, Meldrum B, eds. Antiepileptic Drugs, 4th ed. New York: Raven, 1995:283-300.
20. Browne TR, Szabo GK, Schumacher GE, Greenblatt DJ, Evans JE, Evans BA. Bioavailability studies of drugs with nonlinear pharmacokinetics. I. Tracer dose AUC varies directly with serum concentration. J Clin Pharmacol 1992;32: 1141-1145.
21. Boucher BA, Bombassaro AM, Rasmussen SN, Watridge CB, Achari R, Turlapaty P. Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. J Pharm Sci 1989;78:929-932.
22. Eldon MA, Loewen GR, Voightman RE, et al. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administration intravenously to healthy subjects. Can J Neurol Sci 1993; 20:5180.
23. Eldon MA, Loewen GR, Voightman RE, et al. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin. Clin Pharmacol Ther 1993;53:212.
24. Hussey EK, Dukes GE, Messenheimer JA, et al. Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers. Pharm Res 1990;7:1172-1176.
25. Quon CY, Stampfli HE. In vitro hydrolysis of ACC-9653 (phosphate ester prodrug of phenytoin) by human, dog, rat, blood and tissues. Pharm Res 1986;3(suppl 5):134S.
26. Aweeka F, Alldredge B, Boyer T, Warnock D, Gambertoglio J. Conversion of ACC-9653 to phenytoin in patients with renal or hepatic diseases. Clin Pharmacol Ther 1989;45:152.
27. Broumer K, Matier WL, Quon CY. Absolute bioavailability of phenytoin after IV 3-phosphoryloxymethyl phenytoin disodium. Clin Pharmacol Ther 1988;43:178.
28. Boucher BA, Kugler AR, Hess MM, Feler C. Pharmacokinetics of fosphenytoin, a phenytoin prodrug, following intramuscular administration in critically ill neurosurgery patients. Crit Care Med 1995;23:A78.
29. Garnett WR, Kugler AR, O'Hara KA, Driscoll SM, Pellock JM. Pharmacokinetics of fosphenytoin and phenytoin following intramuscular administration of fosphenytoin substituted for oral phenytoin in epileptic patients. Neurology 1995;45(suppl 4):A248.
30. Rivenburg W, Gerber N, Donn K, et al. Pharmacokinetics and dose proportionality of ACC-9653, a prodrug of phenytoin, in healthy volunteers. Fed Proc 1987;46:708.
31. Kugler AR, Knapp LE, Eldon MA. Rapid attainment of therapeutic phenytoin concentrations following administration of loading doses of fosphenytoin: a meta-analysis. Neurology 1996;46(suppl):A176.
32. Kugler AR, Olson SC, Webb CL, Annesley T, Nordblom GD, Koup JR. Cross-reactivity of fosphenytoin (Cerebyx) in two human phenytoin immunoassays. Pharm Res 1994;11:S102.
33. Varia SA, Schuller S, Sloan KB, Stella VJ. Phenytoin prodrugs. III. Water-soluble prodrugs for oral and parenteral use. J Pharm Sci 1984;73:1068-1080.
34. Baron B, Hankin S, Knapp L. Incidence of complications with intravenous administration of fosphenytoin (Cerebyx) compared with dilantin. Neurology 1995;45(suppl 4):248-249.
35. Dean JC, Smith KR, Boucher BA, et al. Safety, tolerance and pharmacokinetics of intramuscular fosphenytoin, a phenytoin prodrug in neurosurgery patients. Epilepsia 1993;34(suppl 6): 111.
36. Donn KH, Drissel DA, Quon CY. Systemic availability and pharmacokinetics of phenytoin after intramuscular ACC-9653, a phenytoin prodrug. Epilepsia 1987;27:587-588.
37. Dukes GE, Donn KL, Bouwer KLR, Jamerson BD. Comparison of venous irritation secondary to IV administration of phenytoin and ACC-9653, a phenytoin prodrug. Pharmacotherapy 1988;8:133.
38. Fischer J, Turnbull T, Uthman B, Wilder BJ. Safety, tolerance, and pharmacokinetics of intravenous loading doses of fosphenytoin (Cerebyx) vs dilantin. Neurology 1995;45(suppl 4):202.
39. Fischer PA, Sloan EP, Turnbull TL, Paloucek FP, Delacruz F, Fischer JH. Safety and pharmacokinetics of intravenous loading doses of fosphenytoin for the acute treatment of seizures. Epilepsia 1995;36(suppl 3):S160.
40. Jamerson BD, Dukes GE, Brouwer KLR, et al. Venous irritation related to intravenous administration of phenytoin vs fosphenytoin. Pharmacotherapy 1994;14:47-52.
41. Legarda S, Maria BL, Matsuo F, et al. Safety, tolerance, and pharmacokinetics of fosphenytoin, a phenytoin prodrug, in status epilepticus. Epilepsia 1993;34(suppl 6):60.
42. Marriott JG, LeRoy RF, Murray J, Smith H. Injection-site reactions following intramuscular administration of fosphenytoin vs placebo. Can J Neurol Sci 1993;20(suppl 4):S179.
43. Ramsay RE, Barkley GL, Garnett WR, et al. Safety and tolerance of intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Neurology 1995;45(suppl 4):A249.
44. Wilder BJ, Slater J, Malone J, et al. Parenteral loading and maintenance of phenytoin with fosphenytoin, a phenytoin prodrug. Epilepsia 1993;34(suppl 2):27.
45. Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology 1996;46(suppl 1):S17-S19.
46. Boucher BA, Feler C, Dean JC, et al. Safety, tolerance, and pharmacokinetics of fosphenytoin following IM and IV administration in neurosurgery patients. Pharmacotherapy 1996 (in press).
47. Allen FH, Runge JW, Legarda S, et al. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin (Cerebyx) in status epilepticus. Epilepsia 1995;36(suppl 4):90.
48. Ramsay RE, Philbrook B, Martinez DA, Calleramek J, Gallo BV, Acosta A. A double-blinded, randomized safety comparison of rapidly infused intravenous loading doses of fosphenytoin vs phenytoin. Epilepsia 1995;36(suppl 4):90.